These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
These kits are intended for in vitro diagnostic use.
These kits are for research use only and are not intended to be used for diagnostic procedures.
Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
Biological risk products.
Storage between 2 and 8 ° C.
Reactive in liquid form.
Reactive in lyophilized form.
Reactive in frozen form.
Stability after opening at 2-8 ° C.
Products that can be refrozen.
Stability 12 months after refreezing at -20 ° C.
Plasma deficient for the determination of Factor VIII.
From 50 mL
The Safety Data Sheets and Notices are accessible to our registered customers.
Factor VIII is a glycoprotein mainly synthesized by the liver. It circulates in the plasma as bound to VWF which protects it from rapid proteolytic degradation.
It is activated by FXa or thrombin in FVIIIa which will complex with FIXa in the presence of phospholipids to activate FX in FXa.
A patient who is deficient in FVIII has hemophilia A.
This plasma is chemically depleted and assayed at less than 1% for the specific factor.
Freezing the plasmas at -80 °C makes it possible to keep the matrix perfectly intact and to avoid reconstitution.
Our packages contain dry ice for transport.
No additives or preservatives.
Expiration date> 1 year.
Reduces the time needed to set up your test protocols. Ready to use after thawing.